These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20053170)

  • 1. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry.
    Lieberman JA; Javitch JA; Moore H
    Am J Psychiatry; 2008 Aug; 165(8):931-6. PubMed ID: 18676593
    [No Abstract]   [Full Text] [Related]  

  • 3. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic receptor pharmacology and circuitry for the modulation of cognition.
    Bubser M; Byun N; Wood MR; Jones CK
    Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
    Friedman JI
    Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets for treating cognitive dysfunction in schizophrenia.
    Gray JA; Roth BL
    Schizophr Bull; 2007 Sep; 33(5):1100-19. PubMed ID: 17617664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia.
    Rowe AR; Mercer L; Casetti V; Sendt KV; Giaroli G; Shergill SS; Tracy DK
    J Psychopharmacol; 2015 Feb; 29(2):197-211. PubMed ID: 25567553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic Targets in Lung Cancer.
    Spindel ER
    Curr Pharm Des; 2016; 22(14):2152-9. PubMed ID: 26818857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits.
    Philpot RM
    Neurochem Res; 2015 Oct; 40(10):2018-31. PubMed ID: 25652578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic modulation of nucleus accumbens medium spiny neurons.
    de Rover M; Lodder JC; Kits KS; Schoffelmeer AN; Brussaard AB
    Eur J Neurosci; 2002 Dec; 16(12):2279-90. PubMed ID: 12492422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic circuits and signaling in the pathophysiology of schizophrenia.
    Berman JA; Talmage DA; Role LW
    Int Rev Neurobiol; 2007; 78():193-223. PubMed ID: 17349862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies.
    Rao TS; Reid RT; Correa LD; Santori EM; Gardner MF; Sacaan AI; Lorrain D; Vernier JM
    Brain Res; 2003 Oct; 986(1-2):71-81. PubMed ID: 12965231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of cholinergic responses in neurons in the intermediate grey layer of rat superior colliculus.
    Sooksawate T; Isa T
    Eur J Neurosci; 2006 Dec; 24(11):3096-108. PubMed ID: 17156371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cholinergic System: An Emerging Drug Target for Schizophrenia.
    Gibbons A; Dean B
    Curr Pharm Des; 2016; 22(14):2124-33. PubMed ID: 26818859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticholinergicity and cognitive processing in chronic schizophrenia.
    Tracy JI; Monaco C; Giovannetti T; Abraham G; Josiassen RC
    Biol Psychol; 2001 Mar; 56(1):1-22. PubMed ID: 11240312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
    Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
    Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.